PAR (Protease Activated Receptor)-1 antagonist as well as preparation method and application of PAR-1 antagonist
One aspect, the technology of oral preparations, applied in the field of pharmaceutical compositions containing it, can solve problems such as high bleeding risk
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0025]
[0026] Reaction raw materials: self-made, conventional method.
[0027] 1.46 g (10 mmol) compound II , 3.70 g (10 mmol) compound III and 4.15 g (30 mmol) of solid potassium carbonate were stirred overnight in 20 mL of acetonitrile, and then heated to reflux for 3 hours.
[0028] The reaction mixture was cooled slightly and poured into 200 mL ice water, stirred, adjusted to pH = 4 with concentrated hydrochloric acid, extracted with 50 mL × 3 dichloromethane, combined organic phases, washed with brine, dried over anhydrous sodium sulfate, and dried on a rotary evaporator The solvent was evaporated, and the obtained residue was purified by column chromatography to obtain pure I , white solid, MS, m / z = 458 ([M+Na] + ).
Embodiment 2
[0029] Example 2 In vitro platelet aggregation inhibition test
[0030] Pharmacological tests of substances were performed in TRAP (thrombin receptor activating peptide)-induced platelet aggregation in 96-well plates. 3.13% sodium citrate solution was pre-added in the syringe, and then 20 mL of blood from healthy volunteers was drawn in, at 1500 g Platelet-rich plasma (PRP) was separated by centrifugation for 20 minutes and treated with 1 μL PGE1 solution (500 μg / mL in ethanol) / mL PRP. After incubation at room temperature for 5 minutes, they were centrifuged at 1200 g for 20 minutes to remove leukocytes. Transfer the leukocyte-free PRP to 15 mL PP tubes in batches at 5 mL / portion, and centrifuge at 3600 g to pellet the platelets. Then, decant the upper plasma layer and resuspend the platelet pellet from 5 mL of PRP in 1 mL of Tyrode (120 mM NaCl, 2.6 mM KCl, 12 mM NaHCO3, 0.39 mM NaH2PO4, 10 mM HEPES, 0.35% BSA, 5.5 mM Glucose, pH = 7.4) and adjusted to a platelet count o...
Embodiment 3
[0034] Dosage / tablet
[0035] Compound I 5mg
[0036] Microcrystalline Cellulose 80 mg
[0037] Pregelatinized starch 70 mg
[0038] Polyvinylpyrrolidone 6 mg
[0039] Carboxymethyl starch sodium salt 5 mg
[0040] Magnesium stearate 2 mg
[0041]Talc 2 mg.
[0042] Sieve the active ingredient, pregelatinized starch and microcrystalline cellulose, mix well, add polyvinylpyrrolidone solution, mix, make soft material, sieve, make wet granules, dry at 50-60°C, carboxymethyl Sodium starch salt, magnesium stearate and talc powder are pre-screened and then added to the above granules for tableting.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com